Syndax Pharmaceuticals (SNDX) Return on Equity (2016 - 2026)

Syndax Pharmaceuticals' Return on Equity history runs 11 years deep, the most recent figure standing at 0.04% for Q1 2026.

• In Q1 2026, Return on Equity fell 3.0% year-over-year to 0.04%; the TTM figure through Mar 2026 stood at 0.04% (down 3.0% YoY), while the FY2025 annual figure was 0.01%, down 1.0% from the prior year.
• Return on Equity was 0.04% for Q1 2026 at Syndax Pharmaceuticals, down from 0.03% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q1 2022 to a low of 0.04% in Q1 2026.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.0% in 2023.
• The sharpest annual moves came in 2022 and 2026: Return on Equity changed 0 bps in 2022, then fell 3 bps in 2026.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then decreased by 24 bps to 0.0% in 2023, then plunged by 109 bps to 0.01% in 2024, then slumped by 190 bps to 0.03% in 2025, then plunged by 38 bps to 0.04% in 2026.
• The last three Return on Equity figures came in at 0.04% (Q1 2026), 0.03% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.